spacer
home > ebr > > proteolytic enzymes as therapeutic targets
PUBLICATIONS
European Biopharmaceutical Review

Proteolytic Enzymes as Therapeutic Targets

The regulation of protein secretion is central to the proper functioning of eukaryotic organisms. One mode of protein secretion is the generation of soluble fragments of membrane-bound proteins by limited proteolysis through the action of proteases termed secretases, or sheddases. In general, cleavage occurs close to the extracellular face of the membrane, releasing active protein. Proteins secreted in this fashion include some membrane receptors and receptor ligands, ectoenzymes and cell adhesion molecules. Since the proteins concerned are involved in pathophysiological processes, such as neurodegeneration, inflammation and oncogenesis, inhibitors of respective secretases are emerging as promising therapeutic drugs. This article will review a number of methods that have allowed molecular cloning of secretases and discuss different approaches to discovering specific secretase inhibitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Urs Lüthi, Senior Scientist at ESBATech

Dr Urs Lüthi carried out his PhD studies at ESBATech under the supervision of Dr Alcide Barberis and has recently completed his dissertation on the subject of functional screening systems in yeast to identify secretases, targets of secretases and modulators of secretase activity. An essential part of his work focused on the development of the cellular assay for BACE activity that is further developed for small compound inhibitors screens.
He will continue to develop his expertise as a Senior Scientist with ESBATech and will be responsible for the development of similar cell-based assay systems. Urs' academic work was presented at several international conferences and published in peer-reviewed journals.

spacer
Dr Urs Lüthi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Frost & Sullivan: Can Video Telemedicine Improve Care Access in Europe?

LONDON – 8th July 2014 – The video telemedicine market in Europe is poised for rapid growth, with the 2013 market penetration rate of 30 percent expected to rocket up to 50 percent by 2020. Technology advances and the need to provide healthcare access to a geographically fragmented region are factors driving the market. The decreasing prices of low-tier end points such as smart phones and tablets, as well as the higher availability of cloud based telemedicine solutions, will further contribute to market revenues.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Drug Delivery Partnerships

17-18 September 2014, Radisson Blu Hotel, Berlin, Germany

Drug Delivery Partnerships EUROPE is the leading industry drug delivery conference bringing you valuable insights into the latest approaches, formulations, technologies and systems to optimise your product portfolios.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement